Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials for Cancer in United States

7241 results

Sort By:

Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors

Study ID: NCT04299191
Start Date: 2020-09-01
End Date: 2025-09
Study Type

Interventional

Study Phase

Phase2

No. of Participants

28

Intervention / Treatment

Lam561

Sponsor

Laminar Pharmaceuticals

Source: clinicaltrials.gov

Share:
Add to list

Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia

Study ID: NCT06376162
Start Date: 2025-03-18
End Date: 2027-01
Study Type

Interventional

Study Phase

Phase1

No. of Participants

20

Intervention / Treatment

Ziftomen's

Cytarabine

Fludarabine

Sponsor

LLS PedAL Initiative, LLC

Source: clinicaltrials.gov

Share:
Add to list

Met Non Small Cell Cancer Registry (MOMENT)

Study ID: NCT05376891
Start Date: 2022-10-04
End Date: 2028-04-28
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

700

Intervention / Treatment
Sponsor

EMD Serono Research & Development Institute, Inc.

Source: clinicaltrials.gov

Share:
Add to list

A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Patients With HER2-Positive Advanced Solid Tumors

Study ID: NCT05593094
Start Date: 2020-10-15
End Date: 2026-10-30
Study Type

Interventional

Study Phase

Phase1

No. of Participants

210

Intervention / Treatment

ZN-A-1041 50mg BID

ZN-A-1041 100mg BID

ZN-A-1041 200mg BID

ZN-A-1041 400mg BID

ZN-A-1041 600mg BID

ZN-A-1041 800mg BID

ZN-A-1041 1000mg BID

ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase1b

ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase1b

ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase1b

ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase1c

ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase1c

ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase1c

Sponsor

Suzhou Zanrong Pharma Limited

Source: clinicaltrials.gov

Share:
Add to list

Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies

Study ID: NCT06408194
Start Date: 2024-05-13
End Date: 2025-11
Study Type

Interventional

Study Phase

Phase1

No. of Participants

20

Intervention / Treatment

CD22CART infusion

Tisagenlecleucel

Sponsor

Stanford University

Source: clinicaltrials.gov

Share:
Add to list

Evaluating Personalized Therapeutics Clinic (PTC) on Drug-Drug Interactions and Drug-Gene Interactions

Study ID: NCT05166694
Start Date: 2022-11-30
End Date: 2027-11-01
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

1300

Intervention / Treatment

Drug-Drug Interaction Profile

Drug-Gene Interaction Profile

Standard of Care

Sponsor

University of Chicago

Source: clinicaltrials.gov

Share:
Add to list

Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100

Study ID: NCT06065462
Start Date: 2023-11-10
End Date: 2026-01-31
Study Type

Interventional

Study Phase

Phase2

No. of Participants

21

Intervention / Treatment

Supplied

LB-100

Sponsor

M.D. Anderson Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

Evaluation of the Pathobiology of CALR-mutated MPN Cells

Study ID: NCT06480591
Start Date: 2025-01-21
End Date: 2026-02
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

35

Intervention / Treatment

Blood Draw

Sponsor

Wake Forest University Health Sciences

Source: clinicaltrials.gov

Share:
Add to list

A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)

Study ID: NCT05557591
Start Date: 2023-04-21
End Date: 2027-06-07
Study Type

Interventional

Study Phase

Phase2

No. of Participants

100

Intervention / Treatment

BNT116

Cemiplimab

Sponsor

Regeneron Pharmaceuticals

Source: clinicaltrials.gov

Share:
Add to list

Contrast Enhanced Endoscopic Ultrasound in Pancreas Lesions

Study ID: NCT04324294
Start Date: 2020-02-26
End Date: 2025-12-31
Study Type

Interventional

Study Phase

Phase1

No. of Participants

200

Intervention / Treatment

EUS enhanced with contrast to evaluate pancreas

Sponsor

Cedars-Sinai Medical Center

Source: clinicaltrials.gov

Share:
Add to list